Presentation is loading. Please wait.

Presentation is loading. Please wait.

Xenograft regrowth studies.

Published byἈράμ Κόρακας Modified over 5 years ago

Similar presentations

Presentation on theme: "Xenograft regrowth studies."— Presentation transcript:

1 Xenograft regrowth studies.
Xenograft regrowth studies. A, in PC-3 xenografts, combined treatment with Ad.Egr-TNF.11D and doxorubicin produced significant tumor regression compared with Ad.Egr-TNF.11D alone on days 16 (P = 0.025), 20 (P = 0.039), and 23 (P = 0.006). B, in PROb xenografts, significant tumor regression was observed in the tumors receiving combined treatment with Ad.Egr-TNF.11D and doxorubicin compared with Ad.Egr-TNF.11D alone on days 23 (P = 0.027) and 27 (P = 0.015). Day 0, first day of treatment. Points, mean; bars, SEM. Carlos A. Lopez et al. Mol Cancer Ther 2004;3: ©2004 by American Association for Cancer Research

Download ppt "Xenograft regrowth studies."

Similar presentations

A, Effect of folate-FITC (500 nmol/kg, 5 days/week) and/or sunitinib (20 mg/kg daily) therapy on the growth of M109 tumors in Balb/c mice. A, Effect of.

A, Effect of folate-FITC (500 nmol/kg, 5 days/week) and/or sunitinib (20 mg/kg daily) therapy on the growth of M109 tumors in Balb/c mice. A, Effect of.
SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.
Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.
Inhibition of CR HCT-116 (A and B) or CR HT-29 cells (B) xenografts in EPA and/or FuOx-treated SCID mice. Inhibition of CR HCT-116 (A and B) or CR HT-29.

Inhibition of CR HCT-116 (A and B) or CR HT-29 cells (B) xenografts in EPA and/or FuOx-treated SCID mice. Inhibition of CR HCT-116 (A and B) or CR HT-29.
Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.

Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.
Effects of SC144 on in vivo ovarian tumor.

Effects of SC144 on in vivo ovarian tumor.
Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.
Therapeutic activity of gal‐encapsulated cytotoxic drugs on tumor xenografts Therapeutic activity of gal‐encapsulated cytotoxic drugs on tumor xenografts.

Therapeutic activity of gal‐encapsulated cytotoxic drugs on tumor xenografts Therapeutic activity of gal‐encapsulated cytotoxic drugs on tumor xenografts.
Activity of MAC-321 (i. v. and p. o

Activity of MAC-321 (i. v. and p. o
Effect of MI-773 dosing on long-term efficacy.

Effect of MI-773 dosing on long-term efficacy.
Regorafenib inhibits angiogenesis and induces apoptosis.

Regorafenib inhibits angiogenesis and induces apoptosis.
IL-6 signaling affects response to erlotinib in head and neck (HNSCC) cells. IL-6 signaling affects response to erlotinib in head and neck (HNSCC) cells.

IL-6 signaling affects response to erlotinib in head and neck (HNSCC) cells. IL-6 signaling affects response to erlotinib in head and neck (HNSCC) cells.
A, IC50 dose–response curves of SYD985, T-DM1, and ADC isotype control in all USC cell lines tested in vitro (i.e., HER2 3+ cell lines, P =

A, IC50 dose–response curves of SYD985, T-DM1, and ADC isotype control in all USC cell lines tested in vitro (i.e., HER2 3+ cell lines, P =
Immunohistochemical detection of 8-OHdG by use of the 1F7 monoclonal antibody in oligomer-treated PC3 prostate cancer cells. a, control untreated peripheral.

Immunohistochemical detection of 8-OHdG by use of the 1F7 monoclonal antibody in oligomer-treated PC3 prostate cancer cells. a, control untreated peripheral.
A, rate of proliferation of PC3 prostate cancer cells is greatly reduced by treatment with oligomers containing CpG motifs, as assessed by (a) soft agar.

A, rate of proliferation of PC3 prostate cancer cells is greatly reduced by treatment with oligomers containing CpG motifs, as assessed by (a) soft agar.
Diagnostic plots of the TGI PKPD model fitted to the A677 TGI data.

Diagnostic plots of the TGI PKPD model fitted to the A677 TGI data.
Representative Western blot analyses of S-phase and other proteins from PC3 cell lysates obtained 3 days after oligomer (400 nm)/Lipofectin (15 μg/ml)

Representative Western blot analyses of S-phase and other proteins from PC3 cell lysates obtained 3 days after oligomer (400 nm)/Lipofectin (15 μg/ml)
Skin tumor size following ligand activation of PPARβ/δ and inhibition of COX2. Skin tumor size following ligand activation of PPARβ/δ and inhibition of.

Skin tumor size following ligand activation of PPARβ/δ and inhibition of COX2. Skin tumor size following ligand activation of PPARβ/δ and inhibition of.
Stimulatory effect induced by docetaxel, gefitinib, and cyclopamine on MMP (A) and (B) cytosolic cytochrome c level. Stimulatory effect induced by docetaxel,

Stimulatory effect induced by docetaxel, gefitinib, and cyclopamine on MMP (A) and (B) cytosolic cytochrome c level. Stimulatory effect induced by docetaxel,
In vivo assessment of synergistic activity of MV-CEA and RT in a U87 s

In vivo assessment of synergistic activity of MV-CEA and RT in a U87 s

Similar presentations

Ads by Google